Company news
Immuneonco Biopharmaceuticals (shanghai) Inc Class H (HKEX:1541) news
Immuneonco Biopharmaceuticals (shanghai) Inc Class H news releases on 6ix. Latest, Sep 29, 2026: Next Day Disclosure Return
Press releases & updates
Next Day Disclosure Return
September 29, 2026
VOLUNTARY ANNOUNCEMENT - COMPLETION OF CAPITAL INCREASE OF A SUBSIDIARY
September 28, 2026
2026 Interim Report
September 28, 2026
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
July 31, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 2, 2025
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
May 22, 2025